{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:52:58Z","timestamp":1790477578275,"version":"4.1.0"},"reference-count":198,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1053\/j.jvca.2026.04.027","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T15:47:45Z","timestamp":1776440865000},"page":"2505-2523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in Cardiovascular Pharmacotherapy. VIII. Angiotensin II in Vasodilatory Shock"],"prefix":"10.1053","volume":"40","author":[{"given":"Paul S.","family":"Pagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie K.","family":"Freed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2026.04.027_bib0001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.59.3.347","article-title":"Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia","volume":"59","author":"Goldblatt","year":"1934","journal-title":"J Exp Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.65.2.233","article-title":"Studies on experimental hypertension: II. The effect of resection of splanchnic nerves on experimental renal hypertension","volume":"65","author":"Goldblatt","year":"1937","journal-title":"J Exp Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0003","doi-asserted-by":"crossref","first-page":"69","DOI":"10.7326\/0003-4819-11-1-69","article-title":"Studies on experimental hypertension: V. The pathogenesis of experimental hypertension due to renal ischemia","volume":"11","author":"Goldblatt","year":"1937","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0004","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1152\/ajplegacy.1935.112.1.166","article-title":"The relationship between extrinsic renal nerves to the origin of experimental hypertension","volume":"112","author":"Page","year":"1935","journal-title":"Am J Physiol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0002-8703(37)90519-2","article-title":"Hypertension produced by constriction of the renal artery in sympathectomized dogs","volume":"14","author":"Freeman","year":"1937","journal-title":"Am Heart J"},{"key":"10.1053\/j.jvca.2026.04.027_bib0006","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1152\/ajplegacy.1936.116.3.616","article-title":"Hypertension from constriction of the arteries of denervated kidneys","volume":"116","author":"Collins","year":"1936","journal-title":"Am J Physiol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0007","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1172\/JCI100807","article-title":"Experimental hypertension-observations on sustained elevation of systolic and diastolic blood pressure in dogs","volume":"15","author":"Wood","year":"1936","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0008","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1084\/jem.65.5.671","article-title":"Studies on experimental hypertension: III. The production of persistent hypertension in monkeys (Macaque) by renal ischemia","volume":"65","author":"Goldblatt","year":"1937","journal-title":"J Exp Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0009","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1161\/hy1201.101214","article-title":"History of the discovery of the renin-angiotensin system","volume":"38","author":"Basso","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0010","first-page":"401","article-title":"Mecanismo de la hiptensora de la sangre venosa del rinon en isquemia incomplete aguda","volume":"14","author":"Braun-Menendez","year":"1939","journal-title":"Rev Soc Arg Biol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0011","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1084\/jem.71.1.29","article-title":"A crystalline pressor substance (angiotonin) resulting from the reaction of renin and renin-activator","volume":"71","author":"Page","year":"1940","journal-title":"J Exp Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0012","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1021\/ja01578a030","article-title":"Synthesis of a biologically active octapeptide similar to natural isoleucine angiotonin octapeptide","volume":"21","author":"Schwarz","year":"1957","journal-title":"J Am Chem Soc"},{"key":"10.1053\/j.jvca.2026.04.027_bib0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1126\/science.127.3292.242.b","article-title":"Suggested revision of nomenclature: angiotensin","volume":"127","author":"Braun-Menendez","year":"1958","journal-title":"Science"},{"issue":"Suppl 2","key":"10.1053\/j.jvca.2026.04.027_bib0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1524-6175.2006.05836.x","article-title":"Historical perspectives on the management of hypertension","volume":"8","author":"Moser","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.jvca.2026.04.027_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fcvm.2016.00003","article-title":"Timeline of history of hypertension treatment","volume":"3","author":"Saklayen","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0016","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1172\/JCI101265","article-title":"The hemodynamic effects of angiotonin in normal man","volume":"20","author":"Brady","year":"1941","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0017","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/01.CIR.25.1.263","article-title":"Adjunctive use of a biologic pressor agent, angiotensin, in management of shock","volume":"25","author":"Derrick","year":"1962","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0018","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jama.1961.03040490020005","article-title":"Clinical experience with angiotensin II in the treatment of shock","volume":"178","author":"Del Greco","year":"1961","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.04.027_bib0019","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1172\/JCI105256","article-title":"Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin","volume":"44","author":"Cohn","year":"1965","journal-title":"J Clin Invest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1042\/cs0420091","article-title":"The role of angiotensin II in the control of aldosterone in man","volume":"42","author":"Boyd","year":"1972","journal-title":"Clin Sci"},{"key":"10.1053\/j.jvca.2026.04.027_bib0021","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.RES.34.1.69","article-title":"Sensitization of the adrenal cortex to angiotensin II in sodium-deplete man","volume":"34","author":"Oelkers","year":"1974","journal-title":"Circ Res"},{"key":"10.1053\/j.jvca.2026.04.027_bib0022","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0024-3205(85)90507-7","article-title":"Relative biological activities of Asn1-, Val5-angiotensin II, Ile5-angiotensin II and Sar1-angiotensin II in man","volume":"37","author":"Kono","year":"1985","journal-title":"Life Sci"},{"key":"10.1053\/j.jvca.2026.04.027_bib0023","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1388-9842(01)00155-6","article-title":"Angiotensin in cardiac surgery: efficacy in patient on angiotensin converting enzyme inhibitors","volume":"3","author":"Bennett","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.jvca.2026.04.027_bib0024","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s13054-017-1896-6","article-title":"The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature","volume":"21","author":"Busse","year":"2017","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0025","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/CCM.0000000000002441","article-title":"Clinical experience with IV angiotensin II administration: a systematic review of safety","volume":"45","author":"Busse","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0026","unstructured":"Center for Drug Evaluation and Research. Application Number: 209360Orig1s000. US Department of Health and Human Services Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209360Orig1s000PharmR.pdf. Published 2017. Accessed March 1, 2026."},{"key":"10.1053\/j.jvca.2026.04.027_bib0027","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0028","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-074216","article-title":"Advances in the management of chronic kidney disease","volume":"383","author":"Chen","year":"2023","journal-title":"BMJ"},{"key":"10.1053\/j.jvca.2026.04.027_bib0030","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0031","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.jtcvs.2021.02.097","article-title":"Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients","volume":"163","author":"Chow","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0032","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10557-020-07098-3","article-title":"The use of angiotensin II for the treatment of post-cardiopulmonary bypass vasoplegia","volume":"36","author":"Papazisi","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1053\/j.jvca.2026.04.027_bib0033","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/j.jvca.2024.12.022","article-title":"The efficacy and safety of angiotensin II for treatment of vasoplegia in critically ill patients: a systematic review","volume":"39","author":"Kotani","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0034","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1213\/ANE.0000000000007779","article-title":"The renin-angiotensin-aldosterone system in cardiac surgery and angiotensin II therapy for vasoplegia","volume":"142","author":"Zarbock","year":"2026","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0035","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13613-024-01325-y","article-title":"Impaired angiotensin II signaling in septic shock","volume":"14","author":"Picod","year":"2024","journal-title":"Ann Intensive Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0036","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1053\/j.jvca.2026.04.027_bib0037","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1748-1716.1898.tb00272.x","article-title":"Niere und kreislauf","volume":"8","author":"Tigerstedt","year":"1898","journal-title":"Skandinavisches Archiv f\u00fcr Physiologie"},{"key":"10.1053\/j.jvca.2026.04.027_bib0038","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.2009070759","article-title":"Macula densa sensing and signaling mechanisms of renin release","volume":"21","author":"Peti-Peterdi","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0039","first-page":"1","article-title":"Regulation of renin release by local and systemic factors","volume":"161","author":"Schweda","year":"2011","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0040","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/hr.2016.17","article-title":"Structure and functions of angiotensinogen","volume":"39","author":"Lu","year":"2016","journal-title":"Hypertens Res"},{"key":"10.1053\/j.jvca.2026.04.027_bib0041","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/216762a0","article-title":"Conversion of angiotensin I to angiotensin II","volume":"216","author":"Ng","year":"1967","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2026.04.027_bib0042","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/2251142b0","article-title":"Some properties of angiotensin converting enzyme in the lung in vivo","volume":"225","author":"Ng","year":"1970","journal-title":"Nature"},{"key":"10.1053\/j.jvca.2026.04.027_bib0043","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13054-023-04739-5","article-title":"The alternative renin-angiotensin system in critically ill patients: pathophysiology and therapeutic implications","volume":"27","author":"Garcia","year":"2023","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0044","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1152\/physrev.00038.2017","article-title":"Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology","volume":"98","author":"Forrester","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1053\/j.jvca.2026.04.027_bib0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin-angiotensin system in cardiovascular disease","volume":"17","author":"Ocaranza","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0046","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/HYPERTENSIONAHA.113.01274","article-title":"Angiotensin-(1-7)","volume":"63","author":"Santos","year":"2014","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0047","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/01.RES.87.5.e1","article-title":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9","volume":"87","author":"Donoghue","year":"2000","journal-title":"Circ Res"},{"issue":"6 Pt 2","key":"10.1053\/j.jvca.2026.04.027_bib0048","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.HYP.19.6.692","article-title":"In vivo metabolism of angiotensin II by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats","volume":"19","author":"Yamamoto","year":"1992","journal-title":"Hypertension"},{"issue":"1 Pt 2","key":"10.1053\/j.jvca.2026.04.027_bib0049","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/01.HYP.29.1.394","article-title":"Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide","volume":"29","author":"Li","year":"1997","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0050","doi-asserted-by":"crossref","DOI":"10.1053\/j.jvca.2026.02.035","article-title":"Advances in cardiovascular pharmacotherapy. VII. Soluble guanylate cyclase stimulators in pulmonary hypertension and heart failure","volume":"40","author":"Pagel","year":"2026","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0051","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1161\/01.CIR.0000160867.23556.7D","article-title":"G protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor","volume":"111","author":"Kostenis","year":"2005","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0052","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1053\/j.jvca.2026.04.027_bib0053","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/HJH.0000000000000094","article-title":"Angiotensin-(1-9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme\/Ang II axis","volume":"32","author":"Ocaranza","year":"2014","journal-title":"J Hypertens"},{"key":"10.1053\/j.jvca.2026.04.027_bib0054","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/01.mnh.0000441052.44406.92","article-title":"Alamandine: a new member of the angiotensin family","volume":"23","author":"Villela","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.jvca.2026.04.027_bib0055","doi-asserted-by":"crossref","first-page":"48623","DOI":"10.1074\/jbc.C100512200","article-title":"Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase","volume":"276","author":"Albiston","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1053\/j.jvca.2026.04.027_bib0056","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1111\/j.1742-4658.2011.08275.x","article-title":"Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter","volume":"278","author":"Prajapati","year":"2011","journal-title":"FEBS J"},{"key":"10.1053\/j.jvca.2026.04.027_bib0057","article-title":"Multimodal strategy to counteract vasodilation in septic shock","volume":"42","author":"Leone","year":"2023","journal-title":"Anaesth Crit Care Pain Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0058","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s13054-024-05123-7","article-title":"The renin-angiotensin-aldosterone-system in sepsis and its clinical modulation with exogenous angiotensin II","volume":"28","author":"Legrand","year":"2024","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0059","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13054-020-2743-8","article-title":"Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options","volume":"24","author":"Busse","year":"2020","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0060","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1136\/thx.40.10.774","article-title":"Angiotensin converting enzyme and endotoxin induced lung damage in the mouse","volume":"40","author":"Cookson","year":"1985","journal-title":"Thorax"},{"key":"10.1053\/j.jvca.2026.04.027_bib0061","first-page":"23","article-title":"Effect of E. coli endotoxin on rat plasma angiotensin converting enzyme activity in vitro and in vivo","volume":"21","author":"Deitz","year":"1987","journal-title":"Circ Shock"},{"key":"10.1053\/j.jvca.2026.04.027_bib0062","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1378\/chest.91.1.52","article-title":"Angiotensin converting enzyme in bronchoalveolar lavage in ARDS","volume":"91","author":"Idell","year":"1987","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0063","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11626-013-9707-0","article-title":"LPS-induced effects on angiotensin I-converting enzyme expression and shedding in human pulmonary microvascular endothelial cells","volume":"50","author":"Hermanns","year":"2014","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"Suppl 1","key":"10.1053\/j.jvca.2026.04.027_bib0064","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40121-018-0192-3","article-title":"Activated protein C has no effect on pulmonary capillary endothelial function in septic patients with acute respiratory distress syndrome: association of endothelial dysfunction with mortality","volume":"7","author":"Kaziani","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1053\/j.jvca.2026.04.027_bib0065","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13054-023-04518-2","article-title":"Increasing angiotensin-converting enzyme concentrations and absent angiotensin-converting enzyme activity are associated with adverse kidney outcomes in pediatric septic shock","volume":"27","author":"Pode-Shakked","year":"2023","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0066","first-page":"3","article-title":"The plasma kallikrein\/kinin and renin angiotensin systems in blood pressure regulation in sepsis","volume":"10","author":"Shariat-Madar","year":"2004","journal-title":"J Endotoxin Res"},{"key":"10.1053\/j.jvca.2026.04.027_bib0067","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1161\/01.CIR.83.6.2048","article-title":"Mechanism of coronary vasodilation produced by bradykinin","volume":"83","author":"Pelc","year":"1991","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.CIR.85.1.1","article-title":"Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition","volume":"85","author":"Kiowski","year":"1992","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0069","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/01.HYP.23.4.439","article-title":"Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides","volume":"23","author":"Campbell","year":"1995","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0162-3109(98)00038-1","article-title":"Endogenous B1 receptor mediated hypotension produced by contact system activation in the presence of endotoxemia","volume":"40","author":"Schmid","year":"1998","journal-title":"Immunopharmacology"},{"key":"10.1053\/j.jvca.2026.04.027_bib0071","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.HYP.37.2.703","article-title":"Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo","volume":"37","author":"Fernandes","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0072","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1164\/rccm.202010-3873LE","article-title":"Alteration of the renin-angiotensin-aldosterone system in shock: role of the dipeptidyl peptidase 3","volume":"203","author":"Picod","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0073","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13054-021-03471-2","article-title":"Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational international study","volume":"25","author":"Blet","year":"2021","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0074","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.bja.2021.11.021","article-title":"High plasma dipeptidyl peptidase 3 levels are associated with mortality and organ failure in shock: results from the internationa, prospective and observational FROG-ICU cohort","volume":"128","author":"Deniau","year":"2022","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0075","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/HYPERTENSIONAHA.123.21913","article-title":"Circulating dipeptidyl peptidase 3 modulates systemic and renal hemodynamics through cleavage of angiotensin peptides","volume":"81","author":"Picod","year":"2024","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0076","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238039","article-title":"Inhibition of circulation dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study","volume":"15","author":"Deniau","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.04.027_bib0077","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13054-026-05971-5","article-title":"Circulating DPP3 limits efficacy of angiotensin II infusion in septic shock","volume":"30","author":"Van Lier","year":"2026","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0078","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13063-024-07995-0","volume":"25","author":"Teixeira","year":"2024","journal-title":"Trials"},{"key":"10.1053\/j.jvca.2026.04.027_bib0079","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1152\/ajplegacy.1969.216.1.5","article-title":"Inactivation of angiotensin in shock","volume":"216","author":"Itskovitz","year":"1969","journal-title":"Am J Physiol"},{"issue":"Pt 1","key":"10.1053\/j.jvca.2026.04.027_bib0080","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1042\/BJ20040634","article-title":"Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism","volume":"383","author":"Rice","year":"2004","journal-title":"Biochem J"},{"key":"10.1053\/j.jvca.2026.04.027_bib0081","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1097\/CCM.0b013e318183f067","article-title":"Impaired plasma B-type natriuretic peptide clearance in human septic shock","volume":"36","author":"Pirracchio","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0082","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231555","article-title":"Dysregulated activities of proline-specific enzymes in septic shock patients (sepsis-2)","volume":"15","author":"Vliegen","year":"2020","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.04.027_bib0083","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1161\/01.HYP.38.2.177","article-title":"Downregulation of angiotenin II type 1 receptors during sepsis","volume":"38","author":"Bucher","year":"2001","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0084","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.kint.2020.07.047","article-title":"Impaired angiotensin II type 1 receptor signaling contributes to sepsis-induced acute kidney injury","volume":"99","author":"Leisman","year":"2021","journal-title":"Kidney Int"},{"key":"10.1053\/j.jvca.2026.04.027_bib0085","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cyto.2009.10.006","article-title":"Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock","volume":"49","author":"Schmidt","year":"2010","journal-title":"Cytokine"},{"key":"10.1053\/j.jvca.2026.04.027_bib0086","doi-asserted-by":"crossref","first-page":"e945","DOI":"10.1097\/CCM.0000000000003296","article-title":"MicroRNA-155 amplifiies nitric oxide\/cGMP signaling and impairs vascular angiotensin II reactivity in septic shock","volume":"46","author":"Vasques-Novoa","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0087","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1097\/CCM.0b013e318218665a","article-title":"Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock","volume":"39","author":"Nakada","year":"2011","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0088","doi-asserted-by":"crossref","first-page":"R130","DOI":"10.1186\/cc12809","article-title":"The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension","volume":"14","author":"Mederle","year":"2013","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0089","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thx.34.5.594","article-title":"Peripheral vascular resistance and angiotensin II levels during pulsatile and non-pulsatile cardiopulmonary bypass","volume":"34","author":"Taylor","year":"1979","journal-title":"Thorax"},{"key":"10.1053\/j.jvca.2026.04.027_bib0090","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0022-5223(19)34999-2","article-title":"Experimental study in a rabbit model of ischemia-reperfusion lung injury during cardiopulmonary bypass","volume":"103","author":"Kuratani","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0091","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/0003-4975(94)00919-8","article-title":"Pulmonary injury after total or partial cardiopulmonary bypass with thromboxane synthesis inhibition","volume":"59","author":"Friedman","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0092","first-page":"II262","article-title":"Parameters of pulmonary injury after total or partial cardiopulmonary bypass","volume":"90","author":"Friedman","year":"1994","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0093","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jtcvs.2009.08.036","article-title":"Prevention of ischemia\/reperfusion-induced pulmonary dysfunction after cardiopulmonary bypass with terminal leukocyte-depleted lung reperfusion","volume":"139","author":"Kagawa","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0094","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1152\/jappl.1997.82.6.1776","article-title":"Selective endothelial dysfunction in conscious dogs after cardiopulmonary bypass","volume":"82","author":"Zanaboni","year":"1997","journal-title":"J Appl Physiol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0095","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002822","article-title":"Isolated human pulmonary artery structure and function pre- and post-cardiopulmonary bypass surgery","volume":"5","author":"Dora","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1053\/j.jvca.2026.04.027_bib0096","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/cells15040346","article-title":"Endothelin-1 and vasomotor tone following cardioplegic ischemia\/reperfusion and cardiopulmonary bypass","volume":"15","author":"Kant","year":"2026","journal-title":"Cells"},{"key":"10.1053\/j.jvca.2026.04.027_bib0097","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13054-018-1967-3","article-title":"Vasoplegia treatments: the past, the present, and the future","volume":"22","author":"Levy","year":"2018","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0098","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2044.2006.04779.x","article-title":"Association between vasopressor dependence and early outcome in patients after cardiac surgery","volume":"61","author":"Weis","year":"2006","journal-title":"Anaesthesia"},{"key":"10.1053\/j.jvca.2026.04.027_bib0099","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/icvts\/ivy352","article-title":"Risk factors for vasoplegia after cardiac surgery: a meta-analysis","volume":"28","author":"Dayan","year":"2019","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S0022-5223(98)70049-2","article-title":"Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent","volume":"116","author":"Argenziano","year":"1998","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0101","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1378\/chest.116.5.1233","article-title":"Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery","volume":"116","author":"Fransen","year":"1999","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0102","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1213\/00000539-199503000-00007","article-title":"Angiotensin-converting enzyme inhibitors increase vasoconstrictor requirements after cardiopulmonary bypass","volume":"80","author":"Tuman","year":"1995","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0103","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1540-8191.2000.tb00470.x","article-title":"Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance","volume":"15","author":"Carrel","year":"2000","journal-title":"J Card Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0104","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0003-4975(01)02486-9","article-title":"Risk factors for post-cardiopulmonary bypass vasoplegia in patients with preserved left ventricular function","volume":"71","author":"Mekontso-Dessap","year":"2001","journal-title":"Ann Thorac Surg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0105","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/CIRCULATIONAHA.108.814533","article-title":"Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome","volume":"120","author":"Levin","year":"2009","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0106","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100916","article-title":"Predictors and impact of prolonged casoplegia after continuous-flow left ventricular assist device implantation","volume":"3","author":"Lamba","year":"2024","journal-title":"JACC Adv"},{"key":"10.1053\/j.jvca.2026.04.027_bib0107","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1053\/j.jvca.2025.02.023","article-title":"Angiotensin II in vasoplegia: expanding frontiers in hemodynamic therapy","volume":"39","author":"Siddiqui","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0108","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1378\/chest.124.3.1053","article-title":"Vital organ blood flow during hyperdynamic sepsis","volume":"124","author":"De Giantomasso","year":"2003","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0109","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1097\/CCM.0000000000001198","article-title":"Cortical and medullary tissue perfusion and oxygenation in experimental septic acute kidney injury","volume":"43","author":"Calzavacca","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0110","doi-asserted-by":"crossref","first-page":"R190","DOI":"10.1186\/cc8185","article-title":"Angiotensin II in experimental hyperdynamic sepsis","volume":"13","author":"Wan","year":"2009","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0111","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study","volume":"18","author":"Chawla","year":"2014","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13054-016-1306-5","article-title":"The use of angiotensin II in distributive shock","volume":"20","author":"Chawla","year":"2016","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0113","article-title":"Redefining the modern paradigm of vasopressor therapy in vasodilatory shock","volume":"27","author":"See","year":"2025","journal-title":"Crit Care Resusc"},{"key":"10.1053\/j.jvca.2026.04.027_bib0114","first-page":"43","article-title":"Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial","volume":"19","author":"Chawla","year":"2017","journal-title":"Crit Care Resusc"},{"key":"10.1053\/j.jvca.2026.04.027_bib0115","first-page":"3","article-title":"The ATHOS-3 trial, angiotensin II and The Three Musketeers","volume":"19","author":"Bellomo","year":"2017","journal-title":"Crit Care Resusc"},{"key":"10.1053\/j.jvca.2026.04.027_bib0116","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0117","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2026.04.027_bib0118","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0119","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0120","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1097\/01.CCM.0000186759.13325.DC","article-title":"Marked synergism between vasopressin and angiotensin II in a human isolated artery","volume":"33","author":"Hidaka","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0121","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13054-019-2420-y","article-title":"Broad spectrum vasopressors: a new approach to the initial management of septic shock?","volume":"23","author":"Chawla","year":"2019","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0122","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1177\/0885066618818460","article-title":"Novel vasopressore in the treatment of vasodilatory shock: a systematic review of angiotensin II, selepressin, and terlipressin","volume":"35","author":"Rodriguez","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0123","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.110.158220","article-title":"Angiotensin-mediated microvascular thrombosis","volume":"56","author":"Senchenkova","year":"2010","journal-title":"Hypertension"},{"key":"10.1053\/j.jvca.2026.04.027_bib0124","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1586\/erc.10.161","article-title":"Angiotensin II, tissue factor and the thrombotic paradox of hypertension","volume":"8","author":"Celi","year":"2010","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1053\/j.jvca.2026.04.027_bib0125","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/01.CIR.87.6.1969","article-title":"Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function","volume":"87","author":"Ridker","year":"1993","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2026.04.027_bib0126","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001721-199901000-00003","article-title":"Acute effects of angiotensin II on fibrinolysis in healthy volunteers","volume":"10","author":"Larsson","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1053\/j.jvca.2026.04.027_bib0127","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1056\/NEJMe1706903","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Dellinger","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0128","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/SHK.0000000000000879","article-title":"Non-hemodynamic effects of catecholamines","volume":"48","author":"Hartmann","year":"2017","journal-title":"Shock"},{"key":"10.1053\/j.jvca.2026.04.027_bib0129","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40256-018-0297-9","article-title":"FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock","volume":"19","author":"Senatore","year":"2019","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1053\/j.jvca.2026.04.027_bib0130","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0131","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13613-019-0536-5","article-title":"Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial","volume":"9","author":"Ham","year":"2019","journal-title":"Ann Intensive Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0132","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13054-025-05311-z","article-title":"An index of the initial blood pressure response to angiotensin II treatment and its association with clinical outcomes in vasodilatory shock","volume":"29","author":"Leisman","year":"2025","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0133","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13054-020-2733-x","article-title":"Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock","volume":"24","author":"Bellomo","year":"2020","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0134","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","article-title":"Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial","volume":"202","author":"Bellomo","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00134-023-07290-7","article-title":"Angiotensin II","volume":"50","author":"Bellomo","year":"2024","journal-title":"Intensive Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0136","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13054-024-04910-6","article-title":"ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock","volume":"28","author":"Leisman","year":"2024","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0137","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13054-023-04446-1","article-title":"Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial","volume":"27","author":"Wieruszewski","year":"2023","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0138","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","article-title":"Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II","volume":"46","author":"Tumlin","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0139","first-page":"88","article-title":"Angiotensin II for catecholamine-resistant vasodilatory shock in patients with acute kidney injury: a post hoc analysis of the ATHOS-3 trial","volume":"63","author":"Chaba","year":"2025","journal-title":"Shock"},{"key":"10.1053\/j.jvca.2026.04.027_bib0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13613-023-01227-5","article-title":"Angiotensin II treatment is associated with improved oxygenation in ARDS patients with refractory vasodilatory shock","volume":"13","author":"Leisman","year":"2023","journal-title":"Ann Intensive Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0141","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1006\/pulp.1994.1036","article-title":"Acute effects of hypoxaemia and angiotensin II in the human pulmonary vascular bed","volume":"7","author":"Cargill","year":"1994","journal-title":"Pulm Pharmacol"},{"key":"10.1053\/j.jvca.2026.04.027_bib0142","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0008-6363(95)00129-8","article-title":"Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade","volume":"30","author":"Kiely","year":"1995","journal-title":"Cardiovasc Res"},{"key":"10.1053\/j.jvca.2026.04.027_bib0143","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jcrc.2018.12.007","article-title":"Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data","volume":"50","author":"Abril","year":"2019","journal-title":"J Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0144","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1017\/S0266462320000082","article-title":"Angiotensin II for the treatment of distributive shock in the intensive care unit: a US cost-effectiveness analysis","volume":"36","author":"Busse","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0145","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1177\/0885066619872720","article-title":"A retrospective review of angiotensin II use in adult patients with refractory distributive shock","volume":"35","author":"Wong","year":"2020","journal-title":"J Intensive Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0146","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","article-title":"Angiotensin II infusion for shock: a multicenter study of postmarketing use","volume":"159","author":"Wieruszewski","year":"2020","journal-title":"Chest"},{"key":"10.1053\/j.jvca.2026.04.027_bib0147","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1177\/08850666231174870","article-title":"Trajectory of PaO2\/FiO2 ratio in shock after angiotensin II","volume":"38","author":"Wieruszewski","year":"2023","journal-title":"J Intensive Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0148","article-title":"Physiologic response to angiotensin-II treatment for coronavirus disease 2019-induced vasodilatory shock: a retrospective matched cohort study","volume":"2","author":"Leisman","year":"2020","journal-title":"Crit Care Explor"},{"key":"10.1053\/j.jvca.2026.04.027_bib0149","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1053\/j.jvca.2022.07.022","article-title":"Angiotensin II - a brief review and role in severe SARS-COV-2 sepsis","volume":"36","author":"Cara","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0150","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2211370119","article-title":"Angiotensin II enhances bacterial clearance via myeloid signaling in a murine sepsis model","volume":"119","author":"Leisman","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.jvca.2026.04.027_bib0151","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1097\/CCM.0000000000005975","article-title":"Angiotensin II for the treatment of refractory shock: a matched analysis","volume":"51","author":"Smith","year":"2023","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0152","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/SHK.0000000000002109","article-title":"A pilot study of angiotensin II as primary vasopressor in critically ill adults with vasodilatory hypotension: the ARAMIS study","volume":"59","author":"See","year":"2023","journal-title":"Shock"},{"key":"10.1053\/j.jvca.2026.04.027_bib0153","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13054-022-04161-3","article-title":"Myocardial effects of angiotensin II compared to norepinephrine in an animal model of septic shock","volume":"26","author":"Garcia","year":"2022","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0154","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1053\/j.jvca.2025.01.042","article-title":"Evaluation of angiotensin II in patients with catecholamine-resistant vasodilatory shock requiring continuous renal replacement therapy (ANGEL CRRT)","volume":"39","author":"Rettele","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0155","article-title":"Effectiveness of angiotensin II for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU","volume":"4","author":"Quan","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1053\/j.jvca.2026.04.027_bib0156","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1177\/10600280231226132","article-title":"Clinical response to third-line angiotensin-II vs epinephrine in septic shock: a propensity-matched cohort study","volume":"58","author":"Blankenship","year":"2024","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.jvca.2026.04.027_bib0157","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0885066620972943","article-title":"A multicenter observational cohort study of angiotensin II in shock","volume":"37","author":"Smith","year":"2022","journal-title":"J Intensive Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0158","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13613-025-01463-x","article-title":"Alterations in the renin-angiotensin system during septic shock","volume":"15","author":"Bernaroua","year":"2025","journal-title":"Ann Intensive Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0159","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1053\/j.jvca.2025.08.044","article-title":"Real-world experience on angiotensin II and renin usage in patients with distributive shock: a single-center descriptive study","volume":"39","author":"Petrun","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ajem.2023.01.050","article-title":"Efficacy and safety of angiotensin II in cardiogenic shock: a systematic review","volume":"66","author":"Bansal","year":"2023","journal-title":"Am J Emerg Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0161","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s13054-024-05212-7","article-title":"Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials","volume":"28","author":"Kotani","year":"2024","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0162","first-page":"1085","article-title":"Clinical outcomes of angiotensin II therapy in vasoplegic shock: a systematic review and meta-analysis","volume":"14","author":"Alamami","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1053\/j.jvca.2026.04.027_bib0163","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/SHK.0000000000002558","article-title":"Adjunctive vasopressors and short-term mortality in adults with septic shock: a systematic review and meta-analysis","volume":"63","author":"Bauer","year":"2025","journal-title":"Shock"},{"key":"10.1053\/j.jvca.2026.04.027_bib0164","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0331304","article-title":"Early multimodal vasopressor strategy in septic shock (TRICYCLE)-study protocol for a randomized controlled clinical trial","volume":"20","author":"Kalamar","year":"2025","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.04.027_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0304227","article-title":"The REPERFUSE study protocol: the effects of vasopressor therapy on renal perfusion in patients with septic shock-a mechanistically focused randomised control trial","volume":"19","author":"McDonald","year":"2024","journal-title":"PLoS One"},{"key":"10.1053\/j.jvca.2026.04.027_bib0166","unstructured":"See EJ. A phase 2b randomised controlled trial of the renal effects of angiotensin II versus noradrenaline in critically ill patients with vasodilatory shock. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=382467#:\u223c:text=ACTRN12621001043820,ill%20patients%20with%20vasodilatory%20shock. Published 2024. Accessed March 29, 2026."},{"key":"10.1053\/j.jvca.2026.04.027_bib0167","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4103\/aca.aca_98_21","article-title":"Outcomes following the use of angiotensin II in patients with postoperative vasoplegic syndrome: a case series","volume":"25","author":"Konkol","year":"2022","journal-title":"Ann Card Anaesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0168","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1053\/j.jvca.2020.07.087","article-title":"Angiotensin II for critically ill patients with shock after heart transplant","volume":"35","author":"Cutler","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0169","doi-asserted-by":"crossref","first-page":"98","DOI":"10.14797\/mdcvj.576","article-title":"Angiotensin II: a multimodel approach to vasoplegia in a cardiac setting","volume":"17","author":"Sovic","year":"2021","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1053\/j.jvca.2026.04.027_bib0170","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1053\/j.jvca.2019.03.004","article-title":"Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock","volume":"33","author":"Wieruszewski","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0171","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1053\/j.jvca.2019.03.054","article-title":"Use of angiotensin for vasoplegic shock in a combined heart and liver transplant recipient with systolic anterior motion physiology","volume":"33","author":"Wieruszewski","year":"2019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0172","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1053\/j.jvca.2025.01.012","article-title":"Vasoplegia in heart, lung, or liver transplantation: a narrative review","volume":"39","author":"Ortoleva","year":"2025","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0173","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1097\/CCM.0000000000004502","article-title":"Use of angiotensin II in severe vasoplegia after left pneumonectomy requiring cardiopulmonary bypass: a renin response analysis","volume":"48","author":"Trethowan","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0174","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.xjtc.2020.08.007","article-title":"Successful use of angiotensin II for vasoplegia after thoracoabdominal aortic aneurysm repair","volume":"4","author":"Chatterjee","year":"2020","journal-title":"JTCVS Tech"},{"key":"10.1053\/j.jvca.2026.04.027_bib0175","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13054-018-2225-4","article-title":"Angiotensin in ECMO patients with refractory shock","volume":"22","author":"Ostermann","year":"2018","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0176","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s44158-024-00186-y","article-title":"The use of angiotensin II for the management of distributive shock: expert consensus statements","volume":"4","author":"Landoni","year":"2024","journal-title":"J Anesth Analg Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0177","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.jvca.2020.08.001","article-title":"Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: a post-hoc analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study","volume":"35","author":"Klijian","year":"2021","journal-title":"J Cardiothoracic Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0178","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/10600280221099928","article-title":"Evaluation of the addition of angiotensin II in patients with shock after cardiac surgery at a Veterans Affairs Medical Center","volume":"57","author":"Bird","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1053\/j.jvca.2026.04.027_bib0179","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1164\/rccm.202005-2050OC","article-title":"Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients","volume":"203","author":"Kullmar","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0180","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1164\/rccm.202012-4419ED","article-title":"The Yin and Yang of the renin-angiotensin-aldosterone system in acute kidney injury","volume":"203","author":"Legrand","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0181","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1213\/ANE.0000000000005953","article-title":"The association between angiotensin II and renin kinetics in patients after cardiac surgery","volume":"134","author":"Meersch","year":"2022","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0182","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.bja.2023.06.056","article-title":"Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial","volume":"131","author":"Coulson","year":"2023","journal-title":"Br J Anaesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0183","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1213\/ANE.0000000000006839","article-title":"A pilot study of renin-guided angiotensin-II infusion to reduced kidney stress after cardiac surgery","volume":"139","author":"Sadjadi","year":"2024","journal-title":"Anesth Analg"},{"key":"10.1053\/j.jvca.2026.04.027_bib0184","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/anae.15802","article-title":"A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery","volume":"77","author":"Coulson","year":"2022","journal-title":"Anaesthesia"},{"key":"10.1053\/j.jvca.2026.04.027_bib0185","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-095099","article-title":"A prospective double-blind, randomised controlled trial comparing angiotensin II to norepinephrine to reduce length of hospital stay in cardiac surgery patients (the PORTHOS study protocol)","volume":"15","author":"Coulson","year":"2025","journal-title":"BMJ Open"},{"key":"10.1053\/j.jvca.2026.04.027_bib0186","unstructured":"Universit\u00e4t M\u00fcnster. Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II (PAN-AKI). https:\/\/clinicaltrials.gov\/search?cond=nct06615102&viewType=Card. Published 2025. Accessed April 6, 2026."},{"key":"10.1053\/j.jvca.2026.04.027_bib0187","article-title":"Protocol compliance guiding angiotensin II use in post cardiovascular surgery vasoplegia","volume":"4","author":"Ten Lohuis","year":"2022","journal-title":"Crit Care Explor"},{"key":"10.1053\/j.jvca.2026.04.027_bib0188","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1177\/08850666221145864","article-title":"Angiotensin II for vasodilatory hypotension in patients requiring mechanical circulatory support","volume":"38","author":"Wieruszewski","year":"2023","journal-title":"J Intensive Care Med"},{"issue":"8 Pt A","key":"10.1053\/j.jvca.2026.04.027_bib0189","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1053\/j.jvca.2022.01.002","article-title":"Angiotensin II in patients with shock on mechanical circulatory support: a single-center retrospective case series","volume":"36","author":"Mohamed","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13054-019-2337-5","article-title":"Angiotensin II in ECMO: a word of caution","volume":"23","author":"Antonucci","year":"2019","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0191","doi-asserted-by":"crossref","DOI":"10.1097\/CCM.0000000000006433","article-title":"Angiotensin-II and thromboembolic events: a systematic review","volume":"52","author":"Caragata","year":"2024","journal-title":"Crit Care Med"},{"key":"10.1053\/j.jvca.2026.04.027_bib0192","article-title":"Intraoperative use of angiotensin II for severe vasodilatory shock during liver transplantation: a case report","volume":"15","author":"Running","year":"2021","journal-title":"A A Pract"},{"key":"10.1053\/j.jvca.2026.04.027_bib0193","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1089253219877876","article-title":"Angiotensin II in decompensated cirrhosis complicated by septic shock","volume":"24","author":"Coleman","year":"2020","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2026.04.027_bib0194","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3390\/biomedicines12081817","article-title":"Angiotensin II as a vasopressore for perioperative hypotension in solid organ transplant","volume":"12","author":"Benken","year":"2024","journal-title":"Biomedicines"},{"key":"10.1053\/j.jvca.2026.04.027_bib0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078713","article-title":"Angiotensin II in liver transplantation (AngLT-1): protocol of a randomised, double-blind, placebo-controlled trial","volume":"13","author":"Bokoch","year":"2023","journal-title":"BMJ Open"},{"key":"10.1053\/j.jvca.2026.04.027_bib0196","unstructured":"Caragata R. A direct comparison of angiotensin vs. noradrenaline therapy for the management of liver transplantation-associated hypotension: an open-label, randomised feasibility trial (The D\u2019ARTAGNAN Trial). https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=389441. Published 2025. Accessed March 29, 2026."},{"key":"10.1053\/j.jvca.2026.04.027_bib0197","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s44158-024-00150-w","article-title":"Angiotensin II therapy in refractory septic shock: which patient can benefit most? A narrative review","volume":"4","author":"Coloretti","year":"2024","journal-title":"J Anesth Analg Crit Care"},{"key":"10.1053\/j.jvca.2026.04.027_bib0198","first-page":"In Press","article-title":"Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026","author":"Prescott","year":"2026","journal-title":"Intensive Care Med"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026003460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077026003460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:06:08Z","timestamp":1784541968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077026003460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":198,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1053077026003460"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2026.04.027","relation":{},"ISSN":["1053-0770"],"issn-type":[{"value":"1053-0770","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Cardiovascular Pharmacotherapy. VIII. Angiotensin II in Vasodilatory Shock","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2026.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}